Risperdal Is First Drug To Receive Approval For Pediatric Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s Risperdal paves the way for atypical antipsychotics in pediatric schizophrenia and bipolar I disorder market.
You may also be interested in...
Teva Sues FDA To Relist Risperdal Patent
J&J scenario differs from Merck's Zocor fight, attorney tells “The Pink Sheet” DAILY.
Teva Sues FDA To Relist Risperdal Patent
J&J scenario differs from Merck's Zocor fight, attorney tells “The Pink Sheet” DAILY.
Bristol/Otsuka’s Abilify Approved To Treat Bipolar I Patients As Young As Age 10
Abilify now competes in the age 10-17 space with J&J’s Risperdal, approved in August.